Journal Home
Search for

Volume 77, Issue 2, Pages 189-199 (15 September 2005)


View previous. 8 of 28 View next.

Contrasting loxapine to its isomer isoloxapine—the critical role of in vivo D2 blockade in determining atypicality

Sridhar Natesana, Suzi VanderSpeka, José N. Nobregabd, Robert A. McClellandc, Shitij KapuraeCorresponding Author Informationemail address

Received 3 December 2004; received in revised form 1 March 2005; accepted 14 March 2005.

Abstract 

Background

Loxapine is a typical antipsychotic while isoloxapine, its 8Cl-isomer, shows atypicality in some animal models. The basis for this difference is not well understood. The purpose of this study was to systematically compare the two drugs in in vitro and in vivo animal models, and to understand mechanisms underlying their differential typical/atypical profiles.

Methods

The in vitro and in vivo receptor profiles as well as the action of loxapine and isoloxapine on rat conditioned avoidance response (CAR), catalepsy (CAT), striatal FOS expression and prolactin levels were determined. To understand loxapine's typical profile, we added MDL100,907, to provide loxapine+MDL the same in vivo 5-HT2/D2 ratio as isoloxapine, while holding its D2 component constant.

Results

Isoloxapine behaved as an “atypical” antipsychotic demonstrating CAR inhibition, low CAT, no significant prolactin elevation, and minimal FOS expression in the dorsolateral striatum. Loxapine behaved like a typical antipsychotic, showing unexpectedly high in vivo D2 occupancy. Addition of MDL100,907, which resulted in a very high 5-HT2/D2 in vivo ratio, did not alter loxapine+MDL's typical profile.

Conclusions

Loxapine's behaviour as a typical antipsychotic is most likely due to its disproportionately high D2 occupancy. Appropriate action at D2 receptors in vivo, rather than the high 5-HT2/D2 ratio, seems to be critical in determining why isoloxapine behaves like an atypical antipsychotic.

a Schizophrenia-PET program, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada, M5T 1R8

b Neuroimaging Research Section, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada, M5T 1R8

c Department of Chemistry, 80 St. George Street, University of Toronto, Toronto, Ontario, Canada, M5S 3H6

d Department of Pharmacology, 1 King's College Circle, University of Toronto, Toronto, Ontario, Canada, M5S 1A8

e Department of Psychiatry, University of Toronto, 8th Floor, 250 College Street, Toronto, Ontario, Canada, M5T 1R8

Corresponding Author InformationCorresponding author. Centre for Addiction and Mental Health, ARF Site, 33 Russell Street, Toronto, Ontario, Canada, M5S 2S1. Tel.: +1 416 979 6890; fax: +1 416 260 4206.

PII: S0920-9964(05)00119-2

doi:10.1016/j.schres.2005.03.009


View previous. 8 of 28 View next.